RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial

Citation
Moncunill, G., S. C. De Rosa, A. Ayestaran, A. J. Nhabomba, M. Mpina, K. W. Cohen, C. Jairoce, et al. 2017. “RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial.” Frontiers in Immunology 8 (1): 1008. doi:10.3389/fimmu.2017.01008. http://dx.doi.org/10.3389/fimmu.2017.01008.

Published Version
doi:10.3389/fimmu.2017.01008

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492105

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial

Gemma Moncunill1,2,3*, Stephen C. De Rosa2,4†, Aintzane Ayestaran1, Augusto J. Nhabomba3, Maximillian Mpina5, Kristen W. Cohen2, Chenjerai Jairoce3, Tobias Rutishauser6,7, Joseph J. Campo1,3, Jaroslaw Harezlak8, Héctor Sanz1, Núria Diez-Padrisa1, Nana Aba Williams1, Daryl Morris2, John J. Aponte1, Clarissa Valim9,10, Claudia Daubenberger6,7, Carlota Dobaño1,3† and M. Juliana McElrath2,11†

1 iGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clinic – Universitat de Barcelona, Barcelona, Spain, 2 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 3 Centro de Investigación en Saúde de Manhiça (CISM), Maputo, Mozambique, 4 Department of Laboratory Medicine, University of Washington, Seattle, WA, United States, 5 Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania, 6 Swiss Tropical and Public Health Institute, Basel, Switzerland, 7 University of Basel, Basel, Switzerland, 8 Department of Epidemiology and Biostatistics, School of Public Health-Bloomington, Indiana University, Bloomington, IN, United States, 9 Department of Osteopathic Medical Specialties, Michigan State University, East Lansing, MI, United States, 10 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States, 11 Department of Medicine, University of Washington, Seattle, WA, United States

Comprehensive assessment of cellular responses to the RTS,S/AS01E vaccine is needed to understand potential correlates and ultimately mechanisms of protection against malaria disease. Cellular responses recognizing the RTS,S/AS01E-containing circumsporozoite protein (CSP) and Hepatitis B surface antigen (HBsAg) were assessed before and 1 month after primary vaccination by intracellular cytokine staining and 16-color flow cytometry in 105 RTS,S/AS01-vaccinated and 74 rabies-vaccinated participants (controls) in a pediatric phase III trial in Africa. RTS,S/AS01E-vaccinated children had significantly higher frequencies of CSP- and HBsAg-specific CD4+ T cells producing IL-2, TNF-α, and CD40L and HBsAg-specific CD4+ T producing IFN-γ and IL-17 than baseline and the control group. Vaccine-induced responses were identified in both central and effector memory (EM) compartments. EM CD4+ T cells expressing IL-4 and IL-21 were detected recognizing both vaccine antigens. Consistently higher response rates to both antigens in RTS,S/AS01E-vaccinated than comparator-vaccinated children were observed. RTS,S/AS01E induced polyfunctional CSP- and HBsAg-specific CD4+ T cells, with a greater degree of polyfunctionality in HBsAg responses. In conclusion, RTS,S/AS01E vaccine induces T cells of higher functional heterogeneity and polyfunctionality than previously characterized. Responses detected in memory CD4+ T cell compartments may provide correlates of RTS,S/AS01-induced immunity and duration of protection in future correlates of immunity studies.

Keywords: malaria, Plasmodium falciparum, vaccine, cellular immune responses, T cells, intracellular cytokine staining, flow cytometry
INTRODUCTION

A highly efficacious vaccine can substantially contribute to control and eventual elimination of malaria. This life-threatening disease caused an estimated 429,000 deaths in 2015 (1), mainly among sub-Saharan African children. In 2009–2014, the RTS,S/AS01E malaria vaccine was evaluated in a pediatric Phase III trial in Africa (2–4). Vaccine efficacy (VE) against clinical malaria over 1 year post-immunization was moderate (56%) in children enrolled at age 5–17 months and low (31%) in infants enrolled at age 6–12 weeks. Importantly, the protective effects waned quickly over time. To better understand why the RTS,S/AS01E vaccine induced only partial and short-lived protection against malaria, a thorough examination of the immune responses elicited, including different effector functions and memory phenotypes, using qualified or validated assays to ensure appropriate assay sensitivity and specificity to detect small frequencies of antigen-specific cells is needed. RTS,S is a vaccine based on the circumsporozoite protein (CSP) of Plasmodium falciparum, targeting the sporozoite and liver stages of infection. This self-assembling virus-like particle consists of a recombinant protein containing part of CSP fused to the hepatitis B surface antigen (HBsAg) and it is coexpressed with HBsAg alone. In the Phase III trial, RTS,S was formulated with AS01E liposomal adjuvant containing monophosphoryl lipid A and QS21 and was designed to induce strong anti-CSP antibody and T helper (T H) 1 cell responses. Accordingly, in past clinical trials in endemic areas, RTS,S consistently induced high anti-CSP IgG titers (5–11) and moderate T H1 CD4+ T cell responses (5–10). IgG titers have been recently shown to correlate with vaccine-induced protection in secondary analysis of Phase III trial data (12, 13). However, IgG responses do not explain why RTS,S/AS01E VE is moderate or short-lived. Regarding the cellular responses, CD4+ T cells expressing IL-2, TNF-α, and IFN-γ (and CD40L in naïve adults) have been detected by intracellular staining (ICS) or ELISpot (5–11, 14, 15) upon vaccination. In vaccinated naïve adults challenged with P. falciparum-infected mosquitoes, CSP-specific CD4+ T cells and IFN-γ measured by ELISpot were associated with protection (11, 14, 15). One study evaluating RTS,S/AS02D in African children less than 1 year old did not find any association with protection (5), whereas in another one with RTS,S/AS01E in children 5–17 months old observed CSP-specific TNF-α+ CD4+ T cell responses to be associated with a reduced risk of clinical malaria independently of anti-CSP IgG titers (8). Polyfunctional analysis of the ICS data of the later study showed that IFN-γ IL-2-TNF-α+ CD4+ T cells independently predicted reduced risk of clinical malaria, although the response was also detected in control vaccinees, and found a synergistic interaction with anti-CSP IgG titers (9). CD8+ T cell responses were only detected in humans in two studies, one in infants in whom the responses were not correlated with protection and the other in naïve adults (5, 14). Interestingly, NK cells were found to be the main producers of IFN-γ in one field trial, but its association with protection was not assessed (10). Overall, no clear cellular correlates of protection have been demonstrated in African trials although only a limited number of assays restricted to a few immune variables have been studied. There has been no assessment of other cell effector functions, such as T H2 or follicular helper T cells (T FH), or memory phenotypes that may be induced by RTS,S/AS01E and could be correlated with antibody responses and involved in vaccine-induced protection. Interestingly, in the Phase III trial, we detected T H1 responses in supernatants of CSP-stimulated cells associated with protection in RTS,S/AS01E vaccinees, whereas a T H2 cytokine, IL-5, was associated with increased risk for malaria (16). To our knowledge, T H2 responses had only been examined in one previous study in humans, where IL-4 was found elevated in culture supernatants from RTS,S/AS02D-vaccinated infants (5). Lastly, memory T cell subsets have only been examined in a study with malaria-naïve adults who underwent a challenge with P. falciparum-infected mosquitoes after RTS,S vaccination. In that study, central memory T (T CM) cells and effector/effector memory T cells from RTS,S-vaccinated adults produced IL-2 after ex vivo CSP stimulation and frequencies were higher in protected vs. non-protected subjects (15).

Assessing the memory phenotype, the polyfunctionality degree and other relevant functions besides T H1 responses, such as T H2, T H17, cytotoxic, or immunoregulatory responses, may be key to identify functionally complex responses to RTS,S/AS01E and unravel its mode of action. In fact, complexity of the immune response to malaria and the partial and short-lived protection induced by RTS,S/AS01E stresses the need to expand the breadth of immunological profiling to T H2- and regulatory-type markers. This may be particularly relevant in infants in African settings, as they are exposed to prenatal and environmental factors that may modulate immune response to vaccines.

The aim of this study was to analyze RTS,S/AS01E cellular immunogenicity after primary vaccination using two qualified 16-color multiparametric ICS assays that allow the assessment of memory cell subsets and regulatory, cytotoxic, T H1, T H2, T H17, T FH effector functions, most of them never assessed before, and to identify and establish a baseline of cell phenotypes and functional responses to be evaluated in studies of immune correlates of protection elicited by the vaccine. To this end, we analyzed the CSP- and HBsAg-specific cells ex vivo using previously cryopreserved peripheral blood mononuclear cells (PBMC) isolated from a subset of children aged 5–17 months at enrollment from Tanzania and Mozambique and following receipt of either the RTS,S/AS01E vaccine or a comparator rabies vaccine.

MATERIALS AND METHODS

Study Population and Study Design

We performed a study on a subset of 179 children aged 5–17 months from the RTS,S/AS01E Phase III trial (ClinicalTrials.gov NCT00866619), described elsewhere (4): 105 children received RTS,S/AS01E and 74 children received the rabies vaccine as a comparator at study months zero (M0), one, and two. PBMC were collected at M0 before vaccination and approximately 30 days after the third vaccination dose (M3). RTS,S/AS01E-vaccinated and rabies-vaccinated children were randomly selected for this
study among participants with no reported malaria episodes defined by observation of *P. falciparum* parasites on blood smears, identified through passive case detection during 18 months of follow-up after third vaccination dose. Of note, PBMC samples from children who had malaria cases were reserved for future correlates analyses to test the selected markers identified in this study. Samples were collected in two different African centers: Manhiça Health Research Center, Fundação Manhiça (FM-CISM, Mozambique; 120 children), and Ifakara Health Institute and Bagamoyo Research and Training Centre (IHI-BRTC, Tanzania; 59 children). The two sites had low-medium malaria transmission intensity at the time of the study (2–4). Investigators conducted all assays blinded to vaccination status.

**Sample Collection**

Blood was collected in 5 ml sodium citrate (BD Vacutainer® CPT™) tubes. PBMCs were isolated by density gradient centrifugation, cryopreserved and shipped to the Fred Hutchinson Cancer Research Center where the PBMC were thawed and stained (see Methods in Supplementary Material).

**PBMC Stimulations**

Thawed PBMC were rested in a 37°C, 5% CO₂ incubator overnight. The resting step increases the sensitivity of the assay (data not shown), probably by decreasing the stress and activation of PBMC due to the thawing process and exposure to the toxic cryopreservation agent. PBMC were stimulated with peptide pools covering the HBsAg or the CSP antigen present in the RTS,S vaccine (Table S1 in Supplementary Material). Negative controls contained 0.5% DMSO, the diluent for peptide pools, and Staphylococcal enterotoxin B was used as positive control stimulation at 1 µg/ml. Cultures were incubated 6 h at 37°C, 5% CO₂. This short incubation time increases the sensitivity and specificity of the assay to detect antigen-specific cells, avoiding non-specific and secondary immune responses. Further details are found in Supplementary Material.

**Intracellular Cytokine Staining**

Peripheral blood mononuclear cells were stained with one of two 16-color ICS panels that were designed for the study and that had previously undergone assay qualification with a formerly validated panel (17, 18). Cell staining was performed as described (17) (Supplementary Material). Antibody details can be found in Tables S2 and S3 in Supplementary Material. Data were acquired using a BD LSR II flow cytometer (BD Biosciences) directly from the plates using a high throughput sampler. We found some toxicity of HBsAg peptides, but since we could exclude dead cells, data were considered acceptable for analysis. We noted some spillover from CD154 to CXCR5 and therefore, Tfh-like cells were excluded from the analysis. Flow cytometry analysis was performed using FlowJo software (Version 9.9 Tree Star). Gating strategies for both panels are shown in Figures S1 and S2 in Supplementary Material.

**Statistical Analysis**

The raw FCS files and manual gates were imported into the R environment (19) using the OpenCyto framework (20) and cell counts for the cell gates of interest were obtained for all stimulations and subjects.

For the analysis of the effect of vaccination on the frequencies of cells expressing the functional markers, a multivariate linear mixed effect model was fitted using logit-transformed cell frequencies (cells expressing the functional marker/total number of cells within each cell subset) as an outcome. These models are commonly used (21–24) and allow to model jointly the different cell stimulations that each subject sample underwent using random effects. The model included a random intercept for the subject effect nested within stimulation and a random slope for timepoint. In these models, observations generated by different subjects (biological replicates) are assumed to be independent. We included the following predictors in the regression models (as fixed effects): stimulation (CSP, DMSO, or HBsAg and DMSO, as appropriate), time of visit (pre- vs. post-vaccination), and vaccination status (RTS,S/AS01E vs. comparator vaccine), as well as all interactions between the three factors to allow variations of responses across subgroups of vaccinees and time. Linear combination of coefficients in these models allowed addressing specific study questions (details in Supplementary Material). Through these models, we estimated the % change in cell frequencies in RTS,S/AS01E vs. comparator vaccinees at each timepoint, the % change from M0 to M3 in each vaccine group, and the % change in RTS,S/AS01E vs. comparator vaccinees for both timepoints. Statistical significance of comparisons was based on likelihood ratio tests. Antigen-specific responses were analyzed accounting for background, i.e., DMSO stimulation.

To define positivity of responses in each cell subset and subject, we identified the functional markers that were differentially expressed between the antigen (CSP or HBsAg) stimulations and their corresponding background (DMSO control stimulation) for each cell subset, subject, and at each timepoint. Thus, the proportion of cells expressing that marker was compared between the two stimulation conditions for each subject and timepoint. The statistical method used was mixture models for single-cell assays (MIMOSA) (25), using the default algorithm (Expectation–Maximization algorithm) and a false-discovery rate of 0.05%. This method was chosen because it has higher sensitivity and specificity than alternative methods such as Fisher’s exact test (25). A separate model for each functional marker, cell subset, and stimulation was fitted. Once we had defined the positivity or negativity for each functional marker, cell subset, subject, and timepoint, then the proportion of children with positive responses between vaccine groups at baseline or 1-month post-vaccination was compared using two-sided Fisher’s exact test.

Polynomial responses (cell subsets that express multiple functional markers) were analyzed using combinatorial polyfunctionality analysis of antigen-specific T cell subsets (COMPASS) (26). COMPASS models all cell subsets expressing functional markers simultaneously and selects the subsets most likely to have a positive antigen-specific response. The antigen-specific response is quantified by the probability of having a positive response. COMPASS functionality and polyfunctionality scores, summarizing each subject’s polyfunctional profile, were compared...
between vaccine groups using Wilcoxon test. The functionality score is the estimated proportion of antigen-specific cell subsets detected among all possible ones, whereas the polyfunctionality score is similar but weighted by the degree of polyfunctionality.

In addition, COMPASS generates heatmaps that show the posterior probabilities for each modeled cell subset for each subject. CD107a marker was eliminated from MIMOSA and COMPASS analysis, because peptide pool stimulation was associated with a

---

**Figure 1** Continued
non-specific increase in CD107a compared to background, and response positivity could not be defined.

Statistical tests were considered significant at 0.05 α-level. Adjustments for multiple testing were done using Holm (27) and Benjamini–Hochberg (28) approaches. All analyses were conducted using R software. See Supplementary Material for detailed descriptions.

RESULTS

Study Population

We used two different multiparameter ICS panels to assess cellular immune responses specific to the RTS,S/AS01E vaccine antigens. PBMC from 55 RTS,S and 41 comparator vaccinees, and 50 RTS,S and 33 comparator vaccinees were stained with antibody panel 1 (P1) and panel 2 (P2), respectively. The two panels had the same set of core markers, which allowed the exclusion of dead cells, monocytes (CD14), identification of CD4+ and CD8+ T cells (CD4, CD8 and CD3), NK and NK-T cells (CD56), the Tr1 cytokines IFN-γ, IL-2, and TNF-α, the Tr2 cytokine IL-4, the costimulatory molecule CD154 (CD40L), and the cytotoxic marker granzyme B (Figures S1 and S2 in Supplementary Material; Tables S2 and S3 in Supplementary Material). P1 additionally had CD45RA and CCR7 markers that allowed the identification of memory cell subsets, and IL-21, a cytokine related to Trm. Panel 2 (P2) included y8 TCR for the identification of γδ T cells and several functional markers: the regulatory cytokine IL-10, the Tr1 cytokine IL-13, the Tr17 cytokine IL-17, and cytotoxicity marker CD107a. The gating strategy is detailed in Figures S1 and S2 in Supplementary Material. The common set of core markers (lineage and functional markers) allowed the pooled analysis for these markers. Males and females were similarly represented in both study sites and vaccine groups, with a proportion of 59 and 56.8% females in the RTS,S and rabies-vaccinated children, accounting for the pre-vaccination frequencies in a multivariate model. RTS,S/AS01E-vaccinated children had a statistically significant increase of CSP-specific CD4+ T cells expressing IL-2 (217% increase), TNF-α (72.3%), and CD154 (101.4%) from baseline to post-vaccination in contrast to the rabies vaccinees (Figure 1A, i). We observed larger increases over time of HBsAg-specific CD4+ T cells expressing IL-2 (732.2%), TNF-α (346%), and CD154 (268.3%) (Figure 1B, i) in RTS,S/AS01E than in rabies vaccinees.

Figure 1A (ii) and Figure 1B (ii) show the frequencies of CSP- and HBsAg-specific CD4+ T cells after background subtraction. Higher frequencies of CSP- and HBsAg-specific CD4+ T cells expressing the above markers, and additionally HBsAg-specific CD4+ T cells expressing IFN-γ and IL-17 cells, were observed in RTS,S/AS01E vaccinees at post-vaccination compared to baseline and to comparators. No differences were detected between the two vaccine groups at baseline, or from baseline to post-vaccination in comparator vaccinees, the latter suggesting that there was no effect of naturally acquired immunity on cellular responses.

Antigen-specific T cells in memory subsets, defined by CD45RA and CCR7, were analyzed following vaccination. CD4+ TCM (CD45RA−CCR7+) and CD4+ TEM (CD45RA−CCR7−) cells recognized both vaccine antigens. After accounting for baseline frequencies, RTS,S/AS01E vaccinees had more CSP-specific CD4+ TCM cells producing IL-2 and TNF-α, respectively, than comparator vaccinees (Figure 2A, i). Comparisons between vaccine groups at post-vaccination and from baseline to post-vaccination revealed additional responses: higher frequencies of CD4+ TCM expressing IL-2 and TNF-α and CD4+ TEM cells expressing CD154, IL-4 and IL-21, in RTS,S/AS01E than comparator vaccinees (Figure 2A, ii). Regarding HBsAg-specific responses, RTS,S/AS01E vaccinees had increased frequencies of CD4+ TCM producing IL-2, TNF-α and CD154 and CD4+ TEM producing IL-2, TNF-α, CD154 and IL-21 than comparator vaccinees (Figure 2B, i).

Therefore, RTS,S/AS01E vaccination induced CSP and HBsAg-specific CD4+ TCM and CD4+ TEM with Tr1, and additional Tr17 and Tr17+ functions. No overall effect of RTS, S vaccination was detected on the frequencies of terminally differentiated CD4+ T cells (CD45RA+CCR7−), naïve CD4+ T cells (CD45RA−}
Figure 2 | Continued
CCR7), other analyzed cell subsets (NK, NK-T like, γδ T, CD8+ T cells) or on other functional markers (Tables S5 and S6 in Supplementary Material).

**Non-Specific CD4+ T Cell and CD8+ T Cell Responses Induced by RTS,S/AS01E Vaccination**

Analysis of frequencies of cell subsets expressing functional markers in the background (DMSO, serving as the unstimulated control) revealed non-specific responses (i.e., not specific for CSP or HBsAg) upon RTS,S/AS01E vaccination (Figure 3). Accounting for baseline and responses in comparator vaccinees, RTS,S/AS01E vaccination increased the frequencies of CD4+ T cells producing IL-2 or TNF-α or CD154, IL-4, and CD107a (Figure 3A, i). In comparator vaccinees, a decrease in these two subsets from baseline to post-vaccination was detected. Interestingly, RTS,S/AS01E vaccination also increased the frequencies of CD8+ T cells producing IL-4 and CD107a (Figure 3B, i).

Since we detected an effect of RTS,S/AS01E vaccination in the background, we looked at the ex vivo antigen stimulations when not accounting for background. RTS,S/AS01E-vaccinated children had CD4+ T cells and CD8+ T cells expressing IL-4 and CD107a, as was observed for the background alone and, thus, likely reflecting non-specific responses (Figure S3 in Supplementary Material). Additionally, RTS,S/AS01E vaccination increased the frequencies of CD4+ T cells expressing IL-13 and CD8+ T cells expressing CD154 and IL-2 or TNF-α or CD154 following CSP stimulation when not taking background into account (Figure S3 in Supplementary Material). These additional responses in RTS,S/AS01E-vaccinated children were no longer significant when taking into account the background and likely reflect a non-specific effect of RTS,S/AS01E vaccination.

**Higher Proportion of Positive CD4+ T Cell Responses Defined by MIMOSA in RTS,S/AS01E than Comparators**

To assess the vaccine specificity of the antigen-specific T cell responses detected and the rate of responders to the RTS,S/AS01E vaccine (participants whose T-cells responded to stimulation), we determined the positivity of the responses for each subject comparing the frequencies of T cells expressing a functional marker in the antigen-stimulated and unstimulated control conditions for each participant using the MIMOSA statistical method. If a response is truly vaccine specific, one would expect to detect it after vaccination but not at baseline or in the comparator vaccinees. We found a significantly higher proportion of IL-2+, TNF-α+, and CD154+ CD4+ T cell positive CSP-specific responses in RTS,S/AS01E than in comparator vaccinees post-vaccination (Table 1). Response rates for these markers ranged from 24 to 30% in RTS,S/AS01E vaccinees; whereas for comparator vaccinees, there were none or very few responses (Table 1). Similarly, CSP-specific positive responses were absent or very low at baseline, supporting the specificity of the definition of positivity (Table S7 in Supplementary Material).

For HBsAg, we additionally detected more IFN-γ+ and IL-17+ CD4+ T cell positive responses in RTS,S/AS01E than comparator vaccinees at post-vaccination. Rates of HBsAg responders ranged from 26.7 to 76.1% in RTS,S/AS01E vaccinees (Table 1). However, a proportion of comparator vaccinees at post-vaccination and all vaccinees at M0 were also positive (Table 1; Table S7 in Supplementary Material), likely due to the fact that these children received the hepatitis B vaccine during the Expanded Program of Immunization (EPI) before the study. Most of the CSP responders were also HBsAg responders (Figure S4 in Supplementary Material).

When looking at CD4+ TEM and CD4+ TCM cell subsets, we found a significantly higher proportion of CSP responders in RTS,S/AS01E than in comparator vaccinees for IL-2, TNF-α, and CD154 (Table 2). Regarding HBsAg responses, RTS,S/AS01E vaccinees had higher rates of IL-2 and CD154 responses in CD4+ TCM cells and IFN-γ, IL-2, TNF-α, CD154 and IL-21 responses in CD4+ TEM than comparator vaccinees. Very few positive responses to CSP and HBsAg were detected in comparator vaccinees or at baseline (Table 2; Table S8 in Supplementary Material). Almost no positive responses were found in the other cell subsets analyzed (CD4+ TTD, CD4+ TN, NK, NK-T like, γδ T, CD8+ T cells, and memory CD8+ T cell subsets), and no significant differences were detected between vaccination groups for any of the two vaccine antigens (Tables S9–S11 in Supplementary Material).
CSP- and HBsAg-Specific Polyfunctional CD4⁺ T Cell Responses Induced by RTS,S/AS01E

When analyzing the pooled data for the functional markers included in both panels, RTS,S/AS01 vaccinees had significantly higher functionality and polyfunctionality scores for CSP- and HBsAg-specific CD4⁺ T cells than comparator vaccinees (Figures 4A,B). Heatmaps of posterior probabilities of responses showed CSP-specific CD4⁺ T cell responses among subsets coexpressing three markers (IL-2, TNF-α, and CD154), and two markers (TNF-α and CD154; IL-2 and TNF-α) in RTS,S/AS01 vaccinees. The percentages of CD4⁺ T cells coexpressing these markers are shown in Figures 3A and 3B.

**Figure 3** Continued
We also detected CD154+ identified additional highly polyfunctional CD4+ T cell responses. More CD4+ T cells expressing functional markers were detected in RTS,S vaccinees, whereas almost no responses were detected in comparator vaccinees or at baseline (Figure 4A, ii). For HBsAg responses, more CD4+ T cell subsets with positive responses and with higher degree of polyfunctionality were detected in RTS,S/AS01E vaccinees (Figure 4B, ii). Besides the same triple- and double-positive CD4+ T cell responses recognizing CSP antigen, we also detected CD154+ IL-2+ TNF-α+ IFN-γ+ CD4+ T cells and CD154+ IL-2+ TNF-α+ IL4+ CD4+ T cells. By contrast, comparator vaccinees or all vaccinees at baseline had none or weak responses in these subsets that could be explained by background responses to previous malaria exposure or hepatitis B vaccination. Therefore, RTS,S/AS01E induced polyfunctional CD4+ T cells to both vaccine antigens, with a higher degree of polyfunctionality for HBsAg that included Treg and Th2 responses.

When the COMPASS analysis was performed using all the functional makers included in each antibody panel separately, we identified additional highly polyfunctional CD4+ T cell subsets coexpressing IL-13 (for both vaccine antigens) or IL-21 (for HBsAg) in addition to IL-2, TNF-α and CD154 (Figure S5 in Supplementary Material). This further highlights the induction of highly polyfunctional CD4+ T cell subsets with a Th2 and Th17 functions by RTS,S/AS01E. No polyfunctional responses were detected in CD8+ T cells for either vaccine antigen.

**Table 1**: Comparison of proportion of positive CD4+ T cell responses to CSP and hepatitis B surface antigen (HBsAg) between RTS,S/AS01E and comparator vaccinees 1-month post-third vaccination.

| Functional marker | Intracellular cytokine staining panel | Positive/total (%) | P-value |
|-------------------|--------------------------------------|--------------------|---------|
|                   | RTS,S/AS01E                          | Comparator         |         |
| IFN-γ             | P1 and P2                            | 1/100 (1%)         | 0/70 (0%) | 1 1 |
| IL-2              | P1 and P2                            | 30/100 (30%)       | 0/70 (0%) | <0.001 <0.001 |
| CD154             | P1 and P2                            | 24/100 (24%)       | 0/70 (0%) | <0.001 <0.001 |
| IL-4              | P1 and P2                            | 29/100 (29%)       | 5/70 (7.14%) | <0.001 0.002 |
| IL-2 or TNF-α or CD154 | P1 and P2                        | 0/100 (0%)         | 2/70 (2.86%) | 0.17 0.5 |
| IL-21             | P1                                  | 2/52 (3.85%)       | 0/39 (0%) | 0.5 1 |
| IL-10             | P2                                  | 0/48 (0%)          | 0/31 (0%) | 1 1 |
| IL-13             | P2                                  | 5/48 (10.42%)      | 1/31 (3.23%) | 0.39 1 |
| IL-17             | P2                                  | 1/48 (2.08%)       | 0/31 (0%) | 1 1 |

|                   | RTS,S/AS01E                          | Comparator         |         |
| HBsAg             |                                      | Positive/total (%) |         |
|                   | RTS,S/AS01E                          | Comparator         | P-value |
| IFN-γ             |                                      | 34/67 (50.75%)     | 9/50 (18%) | <0.001 0.001 |
| IL-2              |                                      | 49/67 (73.13%)     | 9/50 (18%) | <0.001 <0.001 |
| CD154             |                                      | 48/67 (71.64%)     | 4/50 (8%) | <0.001 <0.001 |
| IL-4              |                                      | 51/67 (76.12%)     | 15/50 (30%) | <0.001 <0.001 |
| IL-21             |                                      | 17/67 (25.37%)     | 6/50 (12%) | 0.1 0.2 |
| IL-10             |                                      | 20/37 (54.05%)     | 12/27 (44.44%) | 0.61 1 |
| IL-13             |                                      | 3/30 (10%)         | 2/23 (8.7%) | 1 1 |
| IL-17             |                                      | 20/30 (66.67%)     | 8/23 (34.78%) | 0.03 0.11 |
|                   |                                      | 8/30 (26.67%)      | 0/23 (0%) | 0.007 0.03 |

**Bold font indicates differences with p-values <0.05.**

<sup>a</sup>Granzyme B was included in the analysis, but not shown because it is constitutively expressed independently of cell stimulation and activation.

<sup>b</sup>Data from markers detected by both staining panels, P1 and P2, are combined.

<sup>c</sup>Raw P, original P-value computed based on two-sided Fisher’s exact test.

<sup>d</sup>Adj P, P-values adjusted for multiple testing using Holm’s approach.

**DISCUSSION**

We provide a detailed characterization of the ex vivo antigen-specific T cell response induced by RTS,S/AS01E vaccination in a pediatric Phase III trial (2–4). In addition to previously described IL-2- and TNF-α-expressing CD4+ T cell responses (5–10), we have identified for the first time in a pediatric field trial Treg2 effector functions and IL-21 in RTS,S vaccinees, attributed the responses to the central memory (CM) and effector memory (EM) compartments, and observed polyfunctional CD4+ T cell...
responses, which may be a key feature of a protective response. Although this analysis was limited to vaccine recipients who did not become infected with *P. falciparum*, this study has identified key immune responses that can be examined in a larger case-control study within this trial.

RTS,S/AS01E vaccination induced distinct antigen-specific CD4+ T cell populations in a subset of children: CSP-specific IL-2, TNF-α, and CD154 CD4+ T cell responses and HBsAg-specific IFN-γ, IL-2, TNF-α, CD154, and IL-17 CD4+ T cell responses. Frequencies of cytokine-positive CD4+ T cells were consistent with the frequencies of IL-2 and TNF-α CSP-specific responses reported previously in RTS,S Phase II trials in endemic areas (5–10). Although no clear associations of TNF-α and IL-2 responses with protection were found in past field studies, they could contribute in RTS,S-induced protection (8, 9). TNF-α is an effector cytokine that may mediate mechanisms of *P. falciparum* pre-erythrocytic protection (29–31) and IL-2 induces proliferation of T cells and amplifies effector functions. CD4+ T cells producing IL-2 may contribute to the memory pool of CD4+ T cells with effector functions since they can be maintained during long periods of time and can develop into IFN-γ-producing T cells following subsequent stimulation (32). Of note, rates of IL-2 CSP responders (23–40% depending on the CD4+ T cell subset) were similar to the estimated VE in the Phase III trial (50% after a year of follow-up or 28% till study end) (4). IL-2 expression can also induce NK activation and secretion of IFN-γ (10, 33, 34), a key effector cytokine involved in malaria protection (35). Contrary to previous findings, we did not detect IFN-γ expression in CD4+ T cells or NK cells ex vivo following CSP stimulation (5, 7, 8, 10, 14). This is probably due to the short stimulation time in our study compared to longer times in whole blood assays from previous studies, which allowed bystander activation of CD4+ T cells and NK cells through IL-2 (10). Remarkably, we detected CD40L expression in antigen-specific CD4+ T cells, in contrast to previous field studies (6, 7).

Importantly, CD4+ T cell responses were detected in CM and EM compartments. Memory phenotypes are relevant to define high-quality and long-lasting responses, for instance, the higher proliferative potential of CM cells has been associated with protection from infection (32, 36–38). TCM responses could, therefore, be involved in long-lasting protection, whereas the CD4+ TCM responses could be associated with the short protection observed in the trial. IL2+, CD154+, and TNF-α CD4+ TCM cells were detected, whereas CD4+ TEM cells had additional effector functions, in accordance with the different cytokine profiles associated with these memory T cell subsets (32, 39, 40).

### Table 2: Comparison of proportion of positive responses to CSP and hepatitis B surface antigen (HBsAg) in memory CD4+ T cell subsets between RTS,S/AS01E and comparator vaccinees 1-month post-third vaccination.

| Memory subset | Functional marker | RTS,S/AS01E | Comparator | P-value | RTS,S/AS01E | Comparator | P-value |
|---------------|------------------|-------------|------------|---------|-------------|------------|---------|
|               | Positive/total (%) | Positive/total (%) | Raw P | Adj P | Positive/total (%) | Positive/total (%) | Raw P | Adj P |
| CM            | IFN-γ            | 1/52 (1.92%) | 0/39 (0%) | 1       | 1           | 1/37 (2.7%) | 0/27 (0%) | 1       | 1 |
| IL-2          | 12/52 (23.08%)   | 0/39 (0%)   | <0.001    | 0.009  | 14/37 (37.84%) | 0/27 (0%) | <0.001 | 0.001 |
| TNF-α         | 8/52 (15.38%)    | 0/39 (0%)   | 0.01     | 0.049  | 8/37 (21.62%) | 0/27 (0%) | 0.02   | 0.058 |
| CD154         | 11/52 (21.15%)   | 0/39 (0%)   | 0.002    | 0.01   | 12/37 (32.43%) | 1/27 (3.7%) | 0.005  | 0.02 |
| IL-4          | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 2/37 (5.41%) | 0/27 (0%) | 0.5    | 1 |
| IL-21         | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 0/37 (0%)   | 0/27 (0%) | 1      | 1 |
| EM            | IFN-γ            | 1/52 (1.92%) | 0/39 (0%) | 1       | 1           | 9/37 (24.32%) | 0/27 (0%) | 0.008  | 0.03 |
| IL-2          | 21/52 (40.38%)   | 0/39 (0%)   | <0.001   | <0.001 | 23/37 (62.16%) | 1/27 (3.7%) | <0.001 | <0.001 |
| TNF-α         | 12/52 (23.08%)   | 0/39 (0%)   | <0.001   | 0.009  | 18/37 (48.65%) | 0/27 (0%) | <0.001 | <0.001 |
| CD154         | 14/52 (26.92%)   | 2/39 (5.13%) | 0.01    | 0.049  | 21/37 (56.76%) | 1/27 (3.7%) | <0.001 | <0.001 |
| IL-4          | 4/52 (7.69%)     | 0/39 (0%)   | 0.13    | 0.46   | 8/37 (21.62%) | 1/27 (3.7%) | 0.07   | 0.19 |
| IL-21         | 7/52 (13.46%)    | 0/39 (0%)   | 0.02    | 0.07   | 16/37 (43.24%) | 2/27 (7.41%) | 0.002  | 0.01 |
| TD            | IFN-γ            | 0/52 (0%)   | 0/39 (0%) | 1       | 0/37 (0%) | 0/27 (0%) | 1       | 1 |
| IL-2          | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 0/37 (0%) | 0/27 (0%) | 1       | 1 |
| TNF-α         | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 0/37 (0%) | 0/27 (0%) | 1       | 1 |
| CD154         | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 0/37 (0%) | 0/27 (0%) | 1       | 1 |
| Naive         | IFN-γ            | 0/52 (0%)   | 0/39 (0%) | 1       | 1           | 1/37 (2.7%) | 2/27 (7.41%) | 0.57   | 1 |
| IL-2          | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 4/37 (10.81%) | 2/27 (7.41%) | 1       | 1 |
| TNF-α         | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 5/37 (13.51%) | 0/27 (0%) | 0.07   | 0.19 |
| CD154         | 0/52 (0%)        | 0/39 (0%)   | 1       | 1      | 1/37 (2.7%) | 0/27 (0%) | 1       | 1 |
| IL-4          | 0/52 (0%)        | 0/39 (0%)   | 0.03    | 0.07   | 0/37 (0%) | 0/27 (0%) | 1       | 1 |
| IL-21         | 0/52 (0%)        | 0/39 (0%)   | 0.01    | 0.02   | 14/37 (37.84%) | 11/27 (40.74%) | 1       | 1 |

Bold font indicates differences with P-values <0.05.
CM, central memory (CD45RA−CCR7+); EM, effector memory (CD45RA−CCR7−); TD, terminally differentiated (CD45RA−CCR7−).
*Granzyme B was included in the analysis, but not shown because it is constitutively expressed independently of cell stimulation and activation.
*Raw P, original P-value computed based on two-sided Fisher’s exact test.
*Adj P, P values adjusted for multiple testing through Benjamini-Hochberg approach.
and studies reporting CD4\(^+\) TEM cells as the main producers of effector cytokines (32, 40). Higher frequencies of CD4\(^+\) TEM cells expressing IL-4, and IL-21 for both vaccine antigens, and IFN-\(\gamma\) for HBsAg, were detected in RTS,S/AS01E-vaccinated children compared to baseline frequencies or comparator vaccinees. T\(_{H2}\) (IL-4) and T\(_{FH}\) (IL-21) effector functions together with CD40L could help to B cells for humoral responses and may correlate with antibody responses (41–44). No responses were detected in CD4\(^+\) TTD cells, a cell subset with high IFN-\(\gamma\) effector function, with no long-term memory potential and fated for death (32).

RTS,S/AS01E vaccination induced polyfunctional CSP- and HBsAg-specific CD4\(^+\) T cells. This finding is particularly important since multifunctional T cells have been associated with higher
responses included IL-4 and CD107a, it could be indicating a detected after vaccination compared with baseline. Since these 
P. falciparum of RTS,S/AS01E may still have an impact on the response against order to assess antigen-specific effects.

This finding of a non-specific effect highlights the importance of be worth noting in the context of the future correlates analyses.

RTS,S/AS01E-vaccinated children. There is increasing evidence of CSP due to the higher proportion of HBsAg compared to the higher proportion of HBsAg than CSP in RTS,S (4:1).

RTS,S/AS01E may have a non-specific effect since higher background CD4+ T cell and CD8+ T cell responses were detected after vaccination compared with baseline. Since these responses included IL-4 and CD107a, it could be indicating a bias to a T effector phenotype and higher cytolytic potential of T cells in RTS,S/AS01E-vaccinated children. There is increasing evidence of non-specific effect of vaccines (47, 48), but a non-specific effect of RTS,S/AS01E may still have an impact on the response against P. falciparum infection. The significance of these responses may be worth noting in the context of the future correlates analyses. This finding of a non-specific effect highlights the importance of correcting for the background (by subtracting background) in order to assess antigen-specific effects.

In this study, we only included children without experiencing a documented malaria episode during the 18 months of follow-up; therefore, the clinical relevance of our findings will be assessed in future correlates studies. The exclusion of malaria cases is unlikely to bias results and affect study conclusions since malaria transmission intensity was low at that time in Manhiça and Bagamoyo and lack of malaria is not likely to be due solely to vaccine-induced protection, but also to lack of exposure to the mosquito-bearing parasite. Another potential limitation of our study relates to the toxicity of HBsAg peptide concentration used. Although this impact could impact cellular responsiveness, we did exclude dead and dying cells in the analysis, and it is likely that any impact would affect both vaccine groups.

The breadth of functions, patterns, and variability of responses to CSP, together with memory phenotypes of responding cell subsets described in our study, reflects a complex response to the RTS,S/AS01 vaccine. These responses, together with anti-CSP IgG data, may provide insights into the impact of protection in a substantial proportion of vaccinees, and may be key in providing correlates for VE and duration of protection.

ETHICS STATEMENT

Approval for the study protocol was obtained from the Ethical Committee of the Hospital Clinic in Barcelona (CEIC, Spain), the National Health and Bioethics Committee (CNBS, Mozambique), the Ethikkommission Beider Basel (EKBB, Switzerland), the National Institutional Review Board (NIMR, Tanzania), the Ifakara Health Institute IRB (IHIIRB, Tanzania), and the PATH’s Research Ethics Committee (REC, USA). Written informed consent was obtained from parents or guardians of participating children in accordance with the Declaration of Helsinki.

AUTHOR CONTRIBUTIONS

Substantial contributions to the conception or design of the work: GM, SR, CDa, CDo, and MJM. Acquisition of samples/data: GM, AN, MM, CJ, TR, JC, CDa, and CDo. Supervision analysis of samples: SR, KC. Analysis of data: GM, AA, JH, JA, DM, and CV. Data management: HS. Project management and coordination: ND-P and NW. Interpretation of data for the work and drafting the manuscript: GM, SR, CDo. Revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: GM, SR, AA, AN, MM, KC, CJ, TR, JC, JH, HS, ND-P, NW, DM, JA, CV, CDa, CDo, MJM.

ACKNOWLEDGMENTS

We wish to thank all the participants of the study and their families. We thank the MAL055 clinical team, the field and laboratory personnel from the CISM, ISGlobal, and IHI-Bagamoyo research and training center, in particular Laura Puyol, Bendita Zavale, Lázaro Quimice, Nelito Ernesto José, Anneth Tumbo, and Helder Bulo, Carole Amroune, and Claudia Hernandez for their administrative and management support. We are very grateful to the Fred Hutch research technologists, in particular, Terry Stewart, Paul Newling, and Kevin Hawkins for their work performing the PBMC stimulations, ICS assays and FlowJo gating. Thanks also to Carol Marty and David Chambless for their logistic laboratory support. We are also grateful to the members of the MAL067 Vaccine Immunology Workgroup and its Working Groups (Statistical and Cellular). We would like to thank Marc Lievens for his help in the selection of samples. We also thank GSK Vaccines and PATH Malaria Vaccine Initiative (MVI) for their support in the conduct of the MAL067 Study. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya.

FUNDING

Supported in part by the PATH Malaria Vaccine Initiative (MVI), and grants from the National Institutes of Health (NIH)—National Institute of Allergy and Infectious Diseases (NIAID), grant number R01AI095789; the HIV Vaccine Trials Network Laboratory Center (HTVN, National Institute of Allergy and Infectious Diseases), grant number U11AI068618; the Human Immunology Project Consortium (HIPC, National Institute of Allergy and Infectious Diseases), grant number P30 AI027757; the Instituto de Salud Carlos III, grant number PS11/00423; and

Moncunill et al. Cellular Responses to RTS,S/AS01E Malaria Vaccine
REFERENCES

1. WHO. World Malaria Report 2016. Geneva: WHO (2016).
2. RTS,S Clinical Trials Partnership, AghaJani ST, Lell B, Fernandes JF, Abosso BP, Methgo BG, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 367:2284–95. doi:10.1056/NEnglJMed.201204219
3. Agnandji ST, Lell B, Souloumoungou SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 365:1863–75. doi:10.1056/NEnglJMed.201102288

RTS Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet (2015) 386;34–45. doi:10.1016/S0140-6736(15)60721-8
5. Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, Aide P, et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun (2009) 77:4502–9. doi:10.1128/IAI.00442-09
6. Agnandji ST, Fendel R, Mestre M, Janssens M, Vekemans J, Held J, et al. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS/S/AS02(D). PLoS One (2011) 6:e18559. doi:10.1371/journal.pone.0018559
7. Ansong D, Asante KP, Vekemans J, Owusu SK, Owusu R, Brobby NAW, et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One (2011) 6:e18891. doi:10.1371/journal.pone.0018891
8. Otolo A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, et al. Circumsporozoite-specific T cell responses in children in vaccinated with RTS,S/AS01 and protection against P.falciparum clinical malaria. PLoS One (2011) 6:e25786. doi:10.1371/journal.pone.0025786
9. Ntung FM, Mwacharo J, Kimani D, Kai O, Moris P, Jongert E, et al. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS One (2012) 7:e52870. doi:10.1371/journal.pone.0052870
10. Horowitz A, Hafalla JCR, King E, Lusingu J, Dekker D, Leach A, et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J Immunol (2012) 188:5054–62. doi:10.4049/jimmunol.1102710
11. Kester K, Cummings JF, Ofori-Aninam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis (2009) 200:337–46. doi:10.1086/600120
12. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med (2014) 11:e1001683. doi:10.1371/journal.pmed.1001685
13. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomized controlled trial. Lancet Infect Dis (2015) 2009;1–9. doi:10.1016/S1473-3099(15)00239-X
14. Sun P, Schweng K, White K, Stoute JA, Cohen J, Ballou WR, et al. Protective immunity induced with malaria vaccine, RTS,S is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol (2003) 171:6961–7. doi:10.4049/jimmunol.171.12.6961
15. Lumsden JM, Schwenk JR, Rein LE, Moris P, Janssens M, Ofori-Aninam O, et al. Protective immunity induced with the RTS,S/as vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS One (2011) 6:e20775. doi:10.1371/journal.pone.0020775
16. Moncunill G, Mpina M, Nhabomba AJ, Aguilar R, Ayestaran A, Sanz H, et al. Distinct TH1 and TH2 cellular responses associated with malaria protection and risk in RTS,S/AS01E vaccinees. Clin Infect Dis (2017). doi:10.1093/cid/cix429
17. Moncunill G, Dubaño C, McElrath MJ, De Rosa SC. OMIP-025: evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining. Cytometry A (2015) 87:289–92. doi:10.1002/cyto.a.22590
18. De Rosa SC, Carter DK, McElrath MJ. OMIP-014: validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining. Cytometry A (2012) 81:1019–21. doi:10.1002/cyto.a.22218
19. R Core Team. R: A Language and Environment for Statistical Computing. (2015). Available from: http://www.r-project.org/
20. Finak G, Frelinger J, Jiang W, Newell EW, Ramey J, Davis MM, et al. OpenCyto: an open source infrastructure for scalable, robust, reproducible, and automated, end-to-end flow cytometry data analysis. PLoS Comput Biol (2014) 10:e1003806. doi:10.1371/journal.pcbi.1003806
21. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley (2011).
22. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwock S, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses (1999) 15:1219–28. doi:10.1089/0898922993103313
23. Burton BK, Thorup AA, Jepsen JR, Poulsen G, Ellersgaard D, Spang KS, et al. Impairments of motor function among children with a familial risk of schizophrenia or bipolar disorder at 7 years old in Denmark: an observational cohort study. Lancet Psychiatry (2017) 4:400–8. doi:10.1016/S2215-0366(17)30103-7
24. Woody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semaglutide for treatment of Alzheimer’s disease. N Engl J Med (2013) 369:341–50. doi:10.1056/NEJMoa1210951
25. Finak G, McDavid A, Chattopadhyay P, Dominguez M, De Rosa S, Roederer M, et al. Mixture models for single-cell assays with applications to vaccine studies. Biostatistics (2014) 15:87–101. doi:10.1093/biostatistics/kxt024
26. Liu L, Finak G, Ushey K, Seshadri C, Hawr T, Frahm N, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol (2015) 33:610–6. doi:10.1038/nbt.3187
27. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat (1979) 6:65–70. doi:10.2307/4615733
28. Benjamini Y, Hochberg Y, Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (1995) 57:289–300. doi:10.2307/2346101
29. Depinay NJ, Frantich JF, Grüner AC, Mauduit M, Chavatte J-MM, Laty AJF, et al. Inhibitory effect of TNF-α on malaria pre-erythrocytic stage development: influence of host hepatoctye/parasite combinations. PLoS One (2011) 6:e17464. doi:10.1371/journal.pone.0017464
30. Mazier D, Réina L, Nussler A, Pried S, Marussig M, Goma J, et al. Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. Immunol Lett (1990) 25:65–70. doi:10.1016/0165-2478(90)90093-6

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.01008/full#supplementary-material.
14. Crotty S. Follicular helper CD4 T cells (TFH). *Ann Rev Immunol* (2011) 29:621–63. doi:10.1146/annurev-immunol-031210-101400

15. Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, et al. Human circulating influenza-CD4+ IFNγ+IL-12+ T cells expand after vaccination, exert helper function, and predict antibody responses. *Proc Natl Acad Sci U S A* (2013) 110:14330–5. doi:10.1073/pnas.1311998110

16. van Kooten C, Banchereau J. CD40-CD40 ligand. *J Leukoc Biol* (2000) 67:2–17.

17. McGuire HM, Vogelzang A, Warren J, Loetsch C, Natividad KD, Chan TD, et al. IL-21 and IL-4 collaborate to shape T-dependent antibody responses. *J Immunol* (2015) 195:5123–35. doi:10.4049/jimmunol.1501463

18. Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. *Nat Med* (2007) 13:843–50. doi:10.1038/nm1592

19. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. *J Virol* (2007) 81:8468–76. doi:10.1128/JVI.00228-07

20. Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. *Clin Ther* (2013) 35:109–14. doi:10.1016/j.clinthera.2013.01.007

21. Kleinijenhuis J, Quintin J, Preijers F, Joosten LAB, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc Natl Acad Sci U S A* (2012) 109:17537–42. doi:10.1073/pnas.1202870109

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Moncunill, De Rosa, Ayestaran, Nhabomba, Mpina, Cohen, Jairoce, Rutishauser, Campo, Harezlak, Sanz, Diez-Padrina, Williams, Morris, Aponte, Valim, Daubenberger, Dobato and McElrath. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.